Mutational Analysis of AKT1 and PIK3CA in Intraductal Papillomas of the Breast with Special Reference to Cellular Components

被引:15
|
作者
Mishima, Chieko [1 ]
Kagara, Naofumi [1 ]
Ikeda, Jun-ichiro [2 ]
Morii, Eiichi [2 ]
Miyake, Tomohiro [1 ]
Tanei, Tomonori [1 ]
Naoi, Yasuto [1 ]
Shimoda, Masafumi [1 ]
Shimazu, Kenzo [1 ]
Kim, Seung Jin [1 ]
Noguchi, Shinzaburo [1 ]
机构
[1] Osaka Univ, Grad Sch Med, Dept Breast & Endocrine Surg, 2-2-E10 Yamadaoka, Suita, Osaka, Japan
[2] Osaka Univ, Grad Sch Med, Dept Pathol, Suita, Osaka, Japan
来源
AMERICAN JOURNAL OF PATHOLOGY | 2018年 / 188卷 / 05期
关键词
POLYMERASE-CHAIN-REACTION; DUCTAL HYPERPLASIA; CLONAL ANALYSIS; MAMMARY-GLAND; CANCER; SUBSEQUENT; PATHWAY; BENIGN; RISK;
D O I
10.1016/j.ajpath.2018.01.005
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The pathologic feature of intraductal papillomas is defined as a papillary structure composed of a fibrovascular stromal core lined by luminal epithelial cells and myoepithelial cells. We used droplet digital PCR for the mutational analysis of AKT1 (E17K) and PIK3CA (H1047R, E542K, and E545K) in 60 papillomas. AKT1 and PIK3CA mutations were detected in 12 (20%) and 17 (28%) of the papillomas, respectively. In five tumors harboring mutations, mutational analysis of AKT1 or PIK3CA was performed separately using luminal epithelial cells and myoepithelial cells sorted using anti cytokeratin 19 antibody and anti a smooth muscle actin antibody. The two types of cells from a given papilloma had the identical mutation. Three patients with the PIK3CA mutation positive papilloma developed breast cancers at the resection site of the papilloma, but none of these subsequent breast cancers had the PIK3CA mutation. These results indicate that a papilloma stems from a bipotent progenitor cell that contains the AKT1 or PIK3CA mutation and proliferates and differentiates to form the papilloma. Papilloma can be a risk factor for developing breast cancer but is unlikely to be its obligate precursor.
引用
收藏
页码:1106 / 1112
页数:7
相关论文
共 50 条
  • [31] Pulmonary epithelial–myoepithelial carcinoma without AKT1, HRAS or PIK3CA mutations: a case report
    Naoki Yanagawa
    Ayaka Sato
    Masao Nishiya
    Masamichi Suzuki
    Ryo Sugimoto
    Mitsumasa Osakabe
    Noriyuki Uesugi
    Hajime Saito
    Tamotsu Sugai
    Diagnostic Pathology, 15
  • [32] Integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
    Stemke-Hale, Katherine
    Gonzalez-Angulo, Ana Maria
    Lluch, Ana
    Neve, Richard M.
    Kuo, Wen-Lin
    Davies, Michael
    Carey, Mark
    Hu, Zhi
    Guan, Yinghui
    Sahin, Aysegul
    Symmans, W. Fraser
    Pusztai, Lajos
    Nolden, Laura K.
    Horlings, Hugo
    Berns, Katrien
    Hung, Mien-Chie
    van de Vijver, Marc J.
    Valero, Vicente
    Gray, Joe W.
    Bernards, Rene
    Mills, Gordon B.
    Hennessy, Bryan T.
    CANCER RESEARCH, 2008, 68 (15) : 6084 - 6091
  • [33] A detailed immunohistochemical analysis of PI3K/AKT/MTOR pathway in lung cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features
    Trigka, E.
    Hardavella, G.
    Saetta, A.
    Kavantzas, N.
    Korkolopoulou, P.
    Anastasiou, N.
    Patsouris, E.
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [34] A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features
    Trigka, Eleni Andriana
    Levidou, Georgia
    Saetta, Angelica A.
    Chatziandreou, Ilenia
    Tomos, Periklis
    Thalassinos, Nikolaos
    Anastasiou, Nikolaos
    Spartalis, Eleftherios
    Kavantzas, Nikolaos
    Patsouris, Efstratios
    Korkolopoulou, Penelope
    ONCOLOGY REPORTS, 2013, 30 (02) : 623 - 636
  • [35] Clinical application of mutational analysis in breast cancer patients: The relevance of PIK3CA analysis for precision medicine
    Cejalvo, J. M.
    Moragon, S.
    Ortega, B.
    Hernando, C.
    Martinez, M.
    Gambardella, V.
    Tarazona Llavero, N.
    Roda, D.
    Burgues, O.
    Alonso, E.
    Simon, S.
    Poveda, J.
    Rentero, P.
    Zuniga, S.
    Bermejo, B.
    Lluch, A.
    Cervantes, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [36] PIK3CA gene mutational analysis in urothelial carcinoma of urinary bladder
    Murphy, K.
    Jadallah, S.
    Hansel, D.
    Cohen, J.
    Toubaji, A.
    Netto, G. J.
    LABORATORY INVESTIGATION, 2008, 88 : 172A - 172A
  • [37] Mutational pattern of PIK3CA exon 20 in circulating DNA in breast cancer
    Ibrahim, Iman Hassan
    Abd El-Aziz, Heba Gamal
    Amer, Noha Nagah Labib
    Abd El-Sameea, Hesham Samir
    SAUDI JOURNAL OF BIOLOGICAL SCIENCES, 2022, 29 (04) : 2828 - 2835
  • [38] PIK3CA gene mutational analysis in urothelial carcinoma of urinary bladder
    Murphy, K.
    Jadallah, S.
    Hansel, D.
    Cohen, J.
    Toubaji, A.
    Netto, G. J.
    MODERN PATHOLOGY, 2008, 21 : 172A - 172A
  • [39] Pulmonary epithelial-myoepithelial carcinoma without AKT1, HRAS or PIK3CA mutations: a case report
    Yanagawa, Naoki
    Sato, Ayaka
    Nishiya, Masao
    Suzuki, Masamichi
    Sugimoto, Ryo
    Osakabe, Mitsumasa
    Uesugi, Noriyuki
    Saito, Hajime
    Sugai, Tamotsu
    DIAGNOSTIC PATHOLOGY, 2020, 15 (01)
  • [40] No evidence for PIK3CA and AKT1 hotspot mutations in squamous cell carcinoma of the skin and basal cell carcinoma
    Hafner, C.
    Landthaler, M.
    Vogt, T.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2009, 7 (09): : 845 - 845